<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40202346</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1866-0452</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>Deutsches Arzteblatt international</Title><ISOAbbreviation>Dtsch Arztebl Int</ISOAbbreviation></Journal><ArticleTitle>Arrhythmogenic Right Ventricular Cardiomyopathy: Diagnosis, Risk Stratification, and Treatment.</ArticleTitle><Pagination><StartPage>229</StartPage><EndPage>234</EndPage><MedlinePgn>229-234</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3238/arztebl.m2024.0264</ELocationID><ELocationID EIdType="pii" ValidYN="Y">arztebl.m2024.0264</ELocationID><Abstract><AbstractText Label="BACKGROUND">Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic heart disease with a prevalence of 1 : 2000 to 1 : 5000. It is characterized by the progressive replacement of heart muscle tissue by fatty and connective tissue. It is associated with a high risk of sudden cardiac death. This review presents the current state of knowledge regarding the diagnostic assessment, risk stratification, and treatment of ARVC.</AbstractText><AbstractText Label="METHODS">This review is based on pertinent publications retrieved by a search in PubMed using the keywords "ARVC" and "arrhythmogenic right ventricular dysplasia". Guidelines, clinical registry studies, meta-analyses, and randomized controlled trials were evaluated.</AbstractText><AbstractText Label="RESULTS">The diagnosis is established with the aid of (long-term) ECG, echocardiography, magnetic resonance imaging, and genetic tests. The ARVC risk calculator is used to assess the risk of ventricular arrhythmia. Patients' participation in sports is restricted. Beta-blockers are recommended for patients with extrasystoles or ventricular tachycardia (grade I recommendation). If beta-blockers alone have an insufficient effect, amiodarone, flecainide or sotalol can be added (grade IIa). For patients with recurrent ventricular tachyarrhythmia, catheter ablation is an option (grade IIa). While there is a clear recommendation (grade I) for defibrillator implantation for patients who have survived sudden cardiac death, the ARVC risk calculator should be used for decisionmaking in patients for whom primary prophylactic implantation is considered (recommendation grade IIa).</AbstractText><AbstractText Label="CONCLUSION">ARVC is associated with an increased risk of sudden cardiac death. Risk assessment remains challenging in the absence of randomized controlled trials, particularly with regard to the primary prophylactic implantation of a defibrillator.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kreimer</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University Hospital of Muenster, Department of Cardiology II - Rhythmology, Muenster; University Hospital of Zurich, Department of Cardiology, Zurich; University Medical Center Mannheim, 1st Medical Department, Mannheim; Heart and Diabetes Center Bad Oeynhausen, Erich &amp; Hanna Klessmann Institute, Bad Oeynhausen; University Hospital St. Josef Hospital Bochum, Department of Cardiology and Rhythmology, Ruhr University Bochum, Bochum; Institute of Physiology, Department for Cellular and Translational Physiology and Institute for Research and Teaching (IFL), Molecular and Experimental Cardiology, Ruhr University Bochum, Bochum.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saguner</LastName><ForeName>Ardan M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Akin</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Milting</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Eckardt</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>El-Battrawy</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Dtsch Arztebl Int</MedlineTA><NlmUniqueID>101475967</NlmUniqueID><ISSNLinking>1866-0452</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019571" MajorTopicYN="Y">Arrhythmogenic Right Ventricular Dysplasia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016757" MajorTopicYN="Y">Death, Sudden, Cardiac</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="Y">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017115" MajorTopicYN="Y">Catheter Ablation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>4</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>9</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40202346</ArticleId><ArticleId IdType="doi">10.3238/arztebl.m2024.0264</ArticleId><ArticleId IdType="pii">arztebl.m2024.0264</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>